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ABSTRACT
Background. In TEMPO 3:4, the vasopressin V2 receptor antag-
onist tolvaptan slowed total kidney volume (TKV) growth and esti-
mated glomerular ﬁltration rate (eGFR) decline relative to placebo.
Methods. TEMPO 4:4 was designed to provide an additional 2
years of data on the long-term safety and efﬁcacy of tolvaptan in
subjects completing TEMPO 3:4. The objective was to assess the
disease-modifying effects of tolvaptan on TKV and eGFR end-
points including change from baseline over the combined
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|duration of TEMPO 3:4 and TEMPO 4:4, and non-inferiority of
slopes during TEMPO 4:4.
Results. Of the 1445 subjects randomized to TEMPO 3:4, 871
(60.3%) enrolled in TEMPO 4:4. Percent changes in TKV from
TEMPO 3:4 baseline to TEMPO 4:4 Month 24 were 29.9% and
31.6% (prior tolvaptan versus prior placebo, P¼ 0.38).
Adjusting for baseline covariates improved the TKV treatment
difference at Month 24 in TEMPO 4:4 from1.70% to 4.15%
between the groups (P¼ 0.04). Slopes of TKV growth during
TEMPO 4:4 were higher in early- versus delayed-treatment
groups (6.16% versus 4.96% per year, P¼ 0.05). Analysis of sec-
ondary eGFR endpoints demonstrated a persistent effect on
eGFR (3.15mL/min/1.73 m2, P< 0.001), and non-inferiority in
eGFR slopes. The safety proﬁle on exposure to tolvaptan in
TEMPO 4:4 was similar to that in TEMPO 3:4.
Conclusions. The results of TEMPO 4:4 support a sustained
disease-modifying effect of tolvaptan on eGFR. The lack of a
sustained treatment difference on TKV may be accounted for
by limitations of the trial design, including loss of randomiza-
tion and baseline imbalances ensuing TEMPO 3:4. The safety
proﬁle was similar to that observed in TEMPO 3:4.
Keywords: autosomal dominant polycystic kidney disease,
chronic kidney disease, polycystin kidney disease, vasopressin,
vasopressin v2 receptor antagonist
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is the
fourth most common cause of end-stage renal disease.
Mutations to polycystin-1 or polycystin-2 disrupt intracellular
calcium homeostasis leading to upregulated adenosine 30,50-
cyclic monophosphate (cAMP) signaling, increased chloride-
driven fluid secretion, cell proliferation and cystogenesis [1, 2].
Cyst proliferation and expansion destroy the renal parenchyma
and cause kidney failure [3]. Vasopressin V2 receptor activation
promotes the generation of cAMP and cystogenesis. Genetic
elimination of circulating vasopressin or pharmacological V2 re-
ceptor blockade inhibits disease progression in animal models
orthologous to human ADPKD, ARPKD (Autosomal Recessive
Polycystic Kidney Disease) and nephronophthisis [4–6].
Tolvaptan, an oral selective vasopressin V2 receptor antag-
onist, lowers cAMP within the epithelial cells of collecting ducts
and distal nephrons, the major sites of cyst development in
ADPKD [7]. In the pivotal TEMPO 3:4 (Tolvaptan Efficacy
and safety in Management of Polycystic kidney disease and its
Outcomes) Clinical Trial, tolvaptan slowed total kidney volume
(TKV) growth by 49.2% relative to placebo (2.8% versus 5.5%
per year, P < 0.001). Most of the treatment effect on TKV,
observed during the first year, was thought to be due to inhib-
ition of fluid secretion into cysts. Smaller incremental benefits
observed throughout the 3 years were attributed to inhibition of
epithelial cell proliferation [8]. Other benefits of treatment
included lower rates of estimated glomerular filtration rate
(eGFR) decline by 26% (0.98mL/min/1.737m2 per year) and of
adjudicated events of renal function decline (equivalent to 30%
reduction in eGFR) and kidney pain (requiring medical inter-
vention or absence from work).
The open-label extension trial TEMPO 4:4 was designed to
provide an additional 2 years of data on long-term safety and ef-
ficacy of tolvaptan in subjects who completed TEMPO 3:4. Its
objective was to assess whether tolvaptan has disease-modifying
effects on TKV growth and eGFR decline, measured by change
from baseline over the combined duration of TEMPO 3:4 and
TEMPO 4:4, and non-inferiority of TKV and eGFR slopes in
early- versus delayed-treated subjects (prior tolvaptan and prior
placebo in TEMPO 3:4) during TEMPO 4:4.
MATERIALS AND METHODS
Trial design and oversight
TEMPO 4:4 was an open-label, extension trial. Participation
was elective for TEMPO 3:4 (clinical trial identifier:
NCT00428948, 2006-002768-24) sites and their subjects. In
Japan, a separate long-term follow-up extension trial was
offered to most subjects (NCT01280721).
Eligible subjects had to enroll within 6 months of successful
completion of TEMPO 3:4 and have an eGFR by Modification
of Diet in Renal Disease (MDRD30mL/min/1.73 m2 within
45 days prior to the baseline visit. Detailed inclusion and exclu-
sion criteria are presented in Supplementary data, Table S1.
Oral tolvaptan was administered in daily split-dose regimens of
45/15mg, 60/30mg or 90/30mg upon waking and approxi-
mately 9 h later. Subjects were titrated to the highest dose toler-
ated in TEMPO 3:4 and were able to titrate up or down per
investigator discretion to maximize tolerability and urine osmo-
lality suppression. Adherence to treatment was self-reported
and monitored by tablet count. Use of diuretics and drugs in-
hibiting the cytochrome P-450 enzyme CYP3A4 were
discouraged.
TEMPO 4:4 (clinical trial identifier: CT01214421, 2010-
018401-10) was in compliance with International Conference on
Harmonization Good Clinical Practice guidelines. The informed
consent form, protocol and amendments were approved by insti-
tutional review boards or independent ethics committees of all
trial sites. A steering committee of investigators and sponsor rep-
resentatives oversaw the trial design and conduct with assistance
of the Independent Data Monitoring Committee and Hepatic
Adjudication Committee.
Trial assessments
Evaluations were performed in-clinic, as previously
described in the TEMPO 3:4 Trial [8], at baseline and on
Months 1, 3, 6 and every 6 months thereafter for 24 months.
Interim laboratory tests [alanine aminotransferase (ALT), as-
partate aminotransferase (AST), alkaline phosphatase, total bili-
rubin and serum creatinine] were measured centrally at 3-
month intervals between the scheduled 6-month visits. In
TEMPO 3:4, the IDMS (isotope dilution mass spectrometry)-
traceable Roche enzymatic method was used to measure cre-
atinine. Initially, assays in TEMPO 4:4 used the rate blank
method, which was corrected (2–3 months into the trial)
through an amendment to the protocol requiring both methods
moving forward. Only serum creatinine values obtained by the
478 V.E. Torres et al.
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IDMS-traceable Roche enzymatic method were used in eGFR
analyses. For subjects who did not complete the trial, final MRI
scans were obtained within 2weeks of withdrawal if not
acquired during the previous 6 months.
Outcome measures
The primary endpoint was the change in TKV from TEMPO
3:4 baseline to TEMPO 4:4 Month 24 in early- versus delayed-
treated subjects. Key secondary endpoints, hierarchal and tested
sequentially, were changes in eGFR [Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI)] from TEMPO 3:4
baseline to TEMPO 4:4 Month 24 and TKV and eGFR slopes
during TEMPO 4:4 in early- and delayed-treated subjects.
Additional analyses included changes from baseline in TKV
and eGFR by prespecified subgroups (e.g. gender). Safety end-
points assessed at all clinic visits comprised reported treatment-
emergent adverse events (TEAEs) and results of clinical labora-
tory tests, vital signs and electrocardiograms.
Statistical analysis
No formal sample size calculation was performed. It was
assumed that up to 900 subjects (i.e. 300 and 600 subjects from
the placebo and tolvaptan groups, respectively) would enroll
from TEMPO 3:4.
The primary efficacy endpoint was tested by Mixed-Effect
Model Repeated Measures (MMRM) with factors of treatment
group (the early-treatment group and the delayed-treatment
group), TEMPO 4:4 visit, treatment group visit interaction, re-
gion, TEMPO 3:4 baseline hypertension, estimated creatinine
clearance and renal volume status, covariate baseline (TEMPO
3:4) and baseline visit interaction with unknown variance covari-
ance structure for the repeated visits was applied. Comparison be-
tween early- and delayed-treatment groups at Month 24 in
TEMPO 4:4 was based on least squares (LS) means at Month 24
of the MMRM to test the superiority of early tolvaptan treatment.
The primary analysis was based on the efficacy sample, with alpha
level 0.05.
Key secondary efficacy endpoints were tested in hierarchical
order using an alpha level of 0.05. Analysis of the first key sec-
ondary endpoint was identical to the analysis of the primary
endpoint, except the model used a heterogeneous Toeplitz vari-
ance covariance matrix. Other key secondary objectives were
tested by a model of random coefficient regression, with fixed
effects of intercept, time, treatment group (early versus delayed),
treatment group time interaction and random effects of inter-
cept and time with unknown variance covariance structure, to
the data collected in TEMPO 4:4, from baseline to Month 24. In
the model, time was a continuous variable, which was equal to
the time spent from baseline to collection of the data.
The 95% confidence interval (CI), based on a contrast be-
tween the early- and delayed-treatment group and obtained
from the treatment group time interaction, was used to test the
non-inferiority null hypotheses. For TKV, log transformed data
were used, and the non-inferiority null hypothesis was rejected
if the upper limit of the 95% CI was less than two-thirds of the
treatment effect in slowing TKV (log-transformed) growth of
the TEMPO 3:4 Trial. The non-inferiority null hypothesis was
rejected if the upper limit of the 95% CI was less than two-thirds
of the treatment effect in slowing eGFR decline in TEMPO 3:4.
Post hoc covariate adjustment analysis was derived from an
MMRM analysis of the percent change from baseline in TKV
employing the model of the primary analysis with the addition
of copeptin and baseline covariates of age, gender, gender visit
interaction, eGFR, eGFR visit interaction and urine albumin/
creatinine ratio (ACR), using an unstructured variance covari-
ance matrix to model the repeated measures.
RESULTS
Subjects
Of 1445 subjects (n ¼ 961 tolvaptan, n ¼ 484 placebo)
randomized in TEMPO 3:4, 948 (excluding Japan) completed
the trial and 871 (91.9% of eligible, 60.3% overall) of them
elected to enroll in TEMPO 4:4 (n ¼ 557, early-treatment
group, 58.0% of those on prior tolvaptan; n ¼ 314, delayed-
treatment group, 64.9% of those on prior placebo) (Figure 1).
The interval between completion of TEMPO 3:4 and initi-
ation of TEMPO 4:4 varied between 13 and 829 days (mean ¼
81 days, median¼ 37 days) but was not different between early-
and delayed-treated subjects (Table 1). Subject demographics
and baseline characteristics of early- and delayed-treatment
groups revealed baseline differences or growing imbalances
from TEMPO 3:4 baseline to TEMPO 4:4 (Table 1) in gender,
copeptin, ACR, TKV and eGFR.
FIGURE 1: Subject disposition in TEMPO 4:4.
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|In TEMPO 4:4, n¼ 50 (9.0%) early-treated subjects and n¼
58 (18.5%) delayed-treated subjects withdrew from the trial
prior to the Month 24 visit. The most common reasons for
withdrawal were adverse event [n¼ 16 (2.9%) early-treated ver-
sus n ¼ 35 (11.1%) delayed-treated] and consent withdrawal [n
¼ 21 (3.8%) versus n ¼ 18 (5.7%)]. All subjects were analyzed
for safety and all but two subjects in the delayed-treated group
were evaluated for efficacy.
Change from baseline in TKV
The primary efficacy endpoint was the maintenance of dif-
ference in percent change in TKV from TEMPO 3:4 baseline to
TEMPO 4:4 Month 24 in early- versus delayed-treatment
groups. TKV increased by 29.9% in early- versus 31.6% in
delayed-treated subjects (P¼ 0.38) (Figure 2). The largest effect
of tolvaptan on TKV growth during TEMPO 3:4 in early-
treated subjects occurred during the first year of treatment and,
while still statistically significant, it became smaller in subse-
quent years. Similarly, the largest effect of tolvaptan on TKV
growth during TEMPO 4:4 in the delayed-treated subjects
occurred in the first year and became smaller in the second year
(Figure 2). Deceleration of TKV growth after reintroduction of
tolvaptan at the initiation of TEMPO 4:4 in the early-treated
subjects was correlated with the time delay between the two
studies (R¼0.19, P< 0.001) (Supplementary data, Figure S1)
and observed mainly in the quartile with the longest off-
treatment duration (treatment effect from TEMPO 4:4 baseline
to M12 comparing Q4 to Q1 2.97% per year, P ¼ 0.06)
(Supplementary data, Figure S2). Since the primary endpoint of
this trial was not reached, prespecified analyses of the secondary
endpoints proceed at the risk of Type I (false positive) error.
Thus, relying upon the results of these analyses, as well as well
as additional post hoc analyses described below, must be con-
sidered exploratory, not confirmatory.
Change from baseline in eGFR
The key secondary endpoint was the change in eGFR from
TEMPO 3:4 baseline to TEMPO 4:4 Month 24 in early- versus
delayed-treatment groups. The nominally significant difference
between early- and delayed-treatment groups was maintained
at each time point, demonstrating that the effect of tolvaptan on
slowing renal function decline in TEMPO 3:4 was maintained
for an additional 2 years in TEMPO 4:4 (3.15mL/min/1.73 m2,
P< 0.001), (Figure 3). Contrary to the changes in TKV, changes
in eGFR during the first year (or during the first month) of
TEMPO 4:4 in early-treated subjects were not correlated with
the time delays between the two studies (Supplementary data,
Figure S3).
Slope of TKV in TEMPO 4:4
TKV slopes in TEMPO 4:4 were higher in early- compared
with delayed-treated subjects (6.16 versus 4.96% per year; treat-
ment difference 1.011, 95% CI, 1.00, 1.02, P ¼ 0.05) (Table 2).
After initiation of tolvaptan in TEMPO 4:4, a substantial effect
on TKV growth during the first year of treatment occurred only
in the delayed-treated subjects (Figure 2), while it was blunted
or absent in the early-treatment group (Supplementary data,
Figure S2). Since the prespecified Statistical Analysis Plan for
non-inferiority required that a TKV slope difference between
treatment groups should have an upper limit of the 95% CI not
greater than two-third of the effect size seen in TEMPO 3:4
(0.0076 in log-10 scale) and the observed upper limit was
Table 1. Demographics characteristics at TEMPO 3:4 and TEMPO 4:4 baseline
Characteristics TEMPO 3:4 TEMPO 4:4
Tolvaptan
(n ¼ 557)
Placebo
(n ¼ 314)
P-value Early-treateda
(n ¼ 557)
Delayed-treateda
(n ¼ 314)
P-value
Male, n (%) 303 (54.4) 159 (50.3) 0.25
Age, years [mean (SD)] 38.9 (6.9) 39.2 (7.3) 0.30 42.2 (6.9) 42.5 (7.2) 0.32
Race, n (%) 0.55
Caucasian 535 (96.1) 302 (96.2)
Black or African American 9 (1.6) 2 (0.6)
Asian 3 (0.5) 2 (0.6)
Other 10 (1.8) 8 (2.5)
Height, cm [mean (SD)] 174.6 (10.4) 173.9 (9.8) 0.32 174.8 (10.3) 174.1 (9.7) 0.35
Weight, kg [mean (SD)] 80.5 (17.7) 79.2 (17.2) 0.30 82.6 (18.4) 81.0 (17.3) 0.23
Age at diagnosis, years [mean (SD)] 27.1 (9.3) 27.2 (9.6) 0.76
TKV, mL [median (IQR)] 1498 (977) 1468 (751) 0.60 1706 (1199) 1835 (1162) 0.05
TKV, % change from TEMPO 3:4 BL 15.8 (17.0) 23.8 (16.9) <0.0001
eGFR, mL/min/1.73 m2 [mean (SD)] 82.2 (20.6) 83.5 (22.6) 0.59 72.3 (24.5) 70.4 (25.0) 0.38
eGFR, change from TEMPO 3:4 BL [mean (SD)] 8.1 (10.3) 10.6 (13.71) 0.003
Blood pressure, mmHg (SD)
Diastolic 82.6 (9.1) 82.7 (9.0) 0.92 80.8 (8.6) 81.1 (8.8) 0.41
Systolic 128.6 (13.2) 128.8 (13.2) 0.86 126.6 (12.4) 127.0 (12.1) 0.68
ACE/ARB use, % (n) 72.0 (401) 71.0 (223) 0.76 81.1 (452) 78.7 (247) 0.38
ACR, mg/mmol (SD) 6.41 (11.75) 6.65 (16.31) 0.85 6.07 (12.46) 7.69 (19.27) 0.04
Copeptina, pmol/L (SD) 8.7 (10.0) 10.9 (25.5) 0.70
Days between TEMPO 3:4 and 4:4, days [mean,
median (range)]
81, 39 (13–566) 80, 36 (13–829) 0.84
Data are given as means with standard deviation (SD), or as median with interquartile range (IQR) when appropriate. BL, baseline.
aThe early-treatment group received tolvaptan in TEMPO 3:4 and the late-treatment group received placebo.
480 V.E. Torres et al.
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|1.02 (0.0099 in log-10 scale), non-inferiority could not be
established.
Slope of eGFR in TEMPO 4:4
eGFR slopes in TEMPO 4:4 were similar in early- and
delayed-treated subjects (3.26 versus 3.14 mL/min/1.73 m2
per year; treatment difference 0.11, 95% CI, 0.75, 0.52, P ¼
0.73) (Table 2). This secondary endpoint met the protocol pre-
defined non-inferiority criterion, since the upper limit of the
95% CI (0.520) is less two-thirds of the eGFR slope difference in
TEMPO 3:4 (0.98, 95% CI 0.60, 1.36). In addition, the upper
limit of the 95% CI (0.52) is also smaller than the lower limit of
FIGURE 3: Change in eGFR from the TEMPO 3:4 baseline to the Month 24 visit of TEMPO 4:4. The inter-trial period is plotted as a 5-month
interval, which approximates the 80th percentile of the treatment holiday (range 13–829 days). Open circles and triangles represent off-treat-
ment time points.
FIGURE 2: Percentage change in TKV from TEMPO 3:4 baseline to TEMPO 4:4 Month 24 visit. Open circles and triangles represent off-treat-
ment time points. Break in treatment from TEMPO 3:4 to TEMPO 4:4 ranged from 13 to 829 days from the Month 36 visit in TEMPO 3:4.
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the TEMPO 3:4 95% CI (0.60), showing that the non-inferiority
criterion based on the FDA (Food and Drug Administration)
M1margin was also met [9].
Impact of non-randomization and covariate imbalance
Randomization and stratification covariates such as gender
were well balanced at baseline in TEMPO 3:4 (ratio of males/
females, 1.06 versus 1.08 in tolvaptan versus placebo groups) [8].
At baseline in TEMPO 4:4, however, there was a gender imbal-
ance between early and delayed treatment groups (ratio of males/
females, 1.19 versus 1.02), which further increased at Month 24
(ratio of males/females, 1.22 versus 1.02) due to higher rates of
withdrawal of females compared with males in both trials.
In the placebo arm of TEMPO 3:4, TKV growth in males
progressed at nearly twice the rate as female subjects (LS mean
change from baseline toM36; 26.0% versus 14.0%, respectively).
In addition, based on TEMPO 3:4, treated by tolvaptan, male
subjects had TKV annual growth rate of 4.4% versus female
subjects of 1.4%. Thus, the drift from balanced randomization
towards an increasing proportion of males in the early-
treatment group would be confounded with the primary end-
point of TKV growth and expected to narrow the treatment dif-
ference in the overall analysis. Analysis by gender reveals the
narrowing to be more significant for females (decreasing to
0.06%, P ¼ 0.98) compared with males (decreasing to
4.48%, P ¼ 0.104), potentially due to a larger acute response
in delayed-treated female subjects in Year 1, (Figure 4A). Thus,
the temporal drift in this covariate may have contributed to a
lack of continued separation for TKV during TEMPO 4:4.
In contrast, the change in renal function in the placebo arm
of TEMPO 3:4 was less influenced by gender (LS mean change
from baseline to FU (follow-up) visit 2; 9.35 versus
10.62mL/min/1.73 m2, male versus female) and, treated by
tolvaptan, male and female subjects in TEMPO 3:4 had a similar
annual rate of eGFR decline (2.80 versus 2.64 mL/min/1.73 m2).
Male and female subjects in TEMPO 3:4 experienced a similar
tolvaptan treatment difference on eGFR over 3 years (3.45 ver-
sus 3.18mL/min/1.73 m2, P ¼ 0.001 versus P ¼ 0.005, respect-
ively) and both genders maintained the treatment difference for
an additional 2 years in TEMPO 4:4 (3.94 versus 2.49mL/min/
1.73 m2, P¼ 0.001 versus 0.04, respectively) (Figure 4B).
Because of the treatment effect of tolvaptan in TEMPO 3:4,
there were additional imbalances in TKV, eGFR and urine ACR
at the baseline of TEMPO 4:4. Adjusting for these imbalances,
other important covariates (age, height, hypertensive status and
region) and baseline characteristics that in post hoc analyses
predicted the response to tolvaptan treatment (urine ACR and
serum copeptin) [10, 11], improved the TKV treatment differ-
ence at Month 24 in TEMPO 4:4 from 1.70% to 4.15% be-
tween the groups and the P-value from P ¼ 0.38 to P ¼ 0.04
(Figure 5 and Supplementary data, Figure S4).
In previous post hoc analyses of TEMPO 3:4, we found that
the beneficial effect of tolvaptan on TKV and eGFR was
greater and/or easier to demonstrate in the subjects with more
severe (as determined either by imaging [12] or genotype
[13]) or more advanced (as determined by CKD stage at base-
line) ADPKD [14]. We also noted that the treatment effect of
tolvaptan on TKV during Year 1 was similar in subjects with
CKD 1, 2 and 3, whereas it was greater during years 2 and 3
in CKD 2 and CKD 3 compared with CKD 1 subjects, where
it was very small [14]. Based on these observations, we per-
formed post hoc analyses to determine whether the treatment
effects of tolvaptan on TKV and eGFR at the end of TEMPO
3:4 were maintained during TEMPO 4:4 in the subjects with
more severe (i.e. image class 1C–E or with truncating PKD1
mutations) or more advanced (CKD 2–3) disease. The treat-
ment effects of tolvaptan on TKV and on eGFR were main-
tained and statistically significant in groups with more severe
(Figures 6 and 7) or more advanced disease (Figure 8). In
imaging class 1B or 2A–B (because of the entry criteria enrich-
ment no class 1A subjects were enrolled in TEMPO 3:4) sub-
jects the tolvaptan treatment effects were not significant either
at the end of TEMPO 3:4 or at the end of TEMPO 4:4. A sig-
nificant difference between tolvaptan- and placebo-treated
CKD 1 subjects and those with non truncating PKD 1 or PKD
2 mutations was observed at the end of TEMPO 3:4, but it
was not sustained at the end of TEMPO 4:4. While the treat-
ment effect on eGFR was present at the end of TEMPO 3:4
and TEMPO 4:4 in CKD 1 subjects, it was more easily demon-
strable in the CKD 2 and CKD 3 subjects.
Adverse events
Overall, 92.3% and 96.5% of early- and delayed-treated sub-
jects, respectively, experienced at least one TEAE over 24
months in TEMPO 4:4 (Table 3). Aquaretic adverse events were
more frequently reported in the delayed-treatment group who
had not been previously exposed to tolvaptan.
Transaminase elevations >3 upper limit of normal (ULN)
during TEMPO 4:4 occurred in 12 of 314 (3.8%) delayed- com-
pared with 14 of 557 (2.5%) early-treated subjects (Table 3).
These rates are similar to those observed in the non-Japanese
population from TEMPO 3:4, where 35 of 840 (4.2%)
Table 2. Slope of TKV and eGFR from baseline to Month 24 in TEMPO 4:4
Treatment Group n Slope (% per year) Treatment difference 95% CI P-value NI margin
TKV (mL)
Early-treateda 509 6.16 1.01 1.00, 1.02 0.046 0.65
Delayed-treateda 268 4.96
eGFR, mL/min/1.73 m2 b
Early-treateda 548 3.26 0.11 0.75, 0.52 0.73 0.65
Delayed-treateda 304 3.14
NI, non-inferiority.
aThe early-treatment group received tolvaptan in TEMPO 3:4 and the late-treatment group received placebo.
beGFR by CKD-EPI equation
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tolvaptan-treated subjects and 4 of 425 (1.6%) placebo-treated
subjects had similar elevations. One delayed-treated subject in
TEMPO 4:4 met the criterion for Hy’s Law (ALT >3 ULN,
BT>2ULN, alkaline phosphatase <2ULN and no alterna-
tive explanation) and recovered completely after discontinu-
ation of tolvaptan [15].
In all, four deaths occurred within the first 24 months of the
open-label extension trial; all deaths occurred after discontinu-
ation of tolvaptan, (Table 3). Causes of death were cardiac ar-
rest, gunshot wound, intracranial aneurysm and subarachnoid
hemorrhage.
DISCUSSION
In the pivotal TEMPO 3:4 clinical trial, tolvaptan slowed the
rates of TKV growth by 49% and eGFR decline by 26%.
TEMPO 4:4 was designed to provide an additional 2 years of
data on the long-term safety and efficacy of tolvaptan in subjects
who completed TEMPO 3:4. Its objective was to ascertain
whether tolvaptan has disease-modifying effects on TKV
growth and eGFR decline [16].
The primary endpoint, that is, preservation of the TKV
benefit between tolvaptan-treated and placebo-treated subjects
obtained at the end of TEMPO 3:4 after both groups received
treatment with tolvaptan for an additional 2 years in TEMPO
4:4, was not achieved. Several factors may account for this re-
sult, including: (i) staggered and delayed roll-over from
TEMPO 3:4 to TEMPO 4:4; (ii) large effect on TKV growth dur-
ing the first year of exposure to tolvaptan and smaller effects in
subsequent years; (iii) blunted or absent acute treatment effect
on TKV upon reintroduction of tolvaptan in early-treated sub-
jects; (iv) imbalance of relevant covariates in TEMPO 4:4 due to
uneven withdrawal and re-enrollment; and (v) different age and
FIGURE 4: Change from baseline in TKV and eGFR by gender. (A) Percentage change in TKV from TEMPO 3:4 baseline to Month 24 in
TEMPO 4:4 for males (left panel) and females (right panel). (B) Change in eGFR from TEMPO 3:4 baseline to Month 24 in TEMPO 4:4 for
males (left panel) and females (right panel). Open circles and triangles represent off-treatment time points.
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disease stage in tolvaptan- and delayed-treated subjects upon
first tolvaptan exposure, along with TKV growth acceleration
with disease progression. The first four factors were not foresee-
able when the trial was designed.
The TEMPO 4:4 Trial design was finalized January 2010
prior to completion of the pivotal TEMPO 3:4 Trial. Since the
trials were not fully integrated, investigators and patients could
elect to participate and opt to delay reentry for up to 6 months.
Delays in ethics committee and administrative approvals led to
further delays in treatment resumption at some sites for many
subjects. Therefore, baseline visits for TEMPO 4:4 were poten-
tially impacted by variable waning of TEMPO 3:4 effects. Half
of the subjects were rolled over into the new trial within 37
days, while those remaining had longer off-treatment periods
(up to 829 days). This obscured the ability to accurately model
off-treatment and re-treatment effects on TKV. It also compli-
cated the factor of ‘time’ and its impact on the stage of disease
progression in our analyses.
Approximately 65% of the tolvaptan-induced reduction in
the rate of TKV relative to placebo over the 3 years of TEMPO
3:4 (9.56% versus 18.75%, i.e. 9.19%) occurred during the first
year of treatment (1.16% versus 5.05%, i.e. 6.27%). This was
consistent with prior reports of 3.1% and 3.7% reductions in
TKV, 1 and 3 weeks after starting treatment, respectively, likely
due to acute effects on fluid secretion [17, 18]. Smaller propor-
tions of the treatment effect, accounting for reductions in TKV
growth of 1.5–2% per year during the 3 years of the trial, were
likely due to effects on proliferation of the cystic epithelium
[19]. This means that the chronic benefit of tolvaptan treatment
may amount to half of the total 49% reduction seen after
TEMPO 3:4. Following discontinuation of tolvaptan at the end
of TEMPO 3:4, we expected that the antisecretory effect would
rapidly dissipate, leaving only one-half (5%) of the overall treat-
ment effect on TKV (10%). The expectation was that early- and
delayed-treated subjects would experience comparable acute ef-
fects on TKV upon initiation of tolvaptan treatment in TEMPO
4:4 and the 5% difference between the groups would be main-
tained during the open-label extension trial. The observed re-
sponse of TKV, however, did not match the predicted response.
During TEMPO 4:4, an acute effect of tolvaptan on TKV
growth at Month 12 was clearly observed in delayed-treated
subjects, but was absent or, in the subjects with a long off-
treatment period, blunted upon reintroduction of tolvaptan in
the early-treated subjects. This different response accounts in
part for the reduction of the TKV difference between the groups
and fully for the superiority of the TKV slope in delayed-treated
subjects during TEMPO 4:4.
The first exposure to tolvaptan occurred at a more advanced
stage of the disease in the delayed-treatment group compared
with the early-treatment group. During TEMPO 3:4, the appar-
ent rate of TKV growth in the placebo-treated subjects
increased annually from 5.05%, to 6.44% and 7.36% in years 1
through 3, respectively. The gradual increase in the rate of TKV
growth as the disease progresses hindered direct comparisons
between the rates of TKV growth in early- and delayed-treated
subjects during TEMPO 3:4 and TEMPO 4:4. In the absence of
a placebo control group in the open-label extension, it is diffi-
cult to compare longer term tolvaptan treatment (5 years) to an
untreated population. Extrapolation of the placebo-treated
group’s trajectory beyond 3 years suggests that the TKV growth
after 5 years would be approximately 40% (Figure 2). The
observed rate of TKV growth in both early- and delayed- treat-
ment groups was approximately 30% over 5 years, supporting
an approximate 25% reduction of TKV growth rate by
FIGURE 5: Percentage change from baseline in TKV when adjusted for covariates. Open circles and triangles represent off-treatment time
points. Blue and gray symbols are slightly offset for ease of interpretation. The following variables were included in an unstructured variance
covariance matrix with ﬁxed factors as in the primary analysis with the addition of copeptin and baseline covariates of age, gender, gender visit
interaction, eGFR, eGFR visit interaction and urine ACR.
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|tolvaptan, beyond its acute effect. These estimates suggest that
both early- and delayed-treated subjects benefited from treat-
ment with tolvaptan.
Measuring the TKV effect is further confounded by the ap-
parent imbalance in certain subject baseline characteristics in
TEMPO 4:4. Gender is an important predictor of TKV growth,
with men generally exhibiting faster TKV growth rates over
time. While the proportion of men and women was nearly
equivalent on randomization in TEMPO 3:4, it became progres-
sively imbalanced during study conduct and upon enrollment
in the extension trial such that nearly 20% more men completed
the TEMPO 4:4 Trial in the early-treatment group versus the
delayed-treatment group. The reasons for this growing imbal-
ance are unclear but include a differential withdrawal rate
during the pivotal trial and selective re-enrollment into
TEMPO 4:4. Additional imbalances in TKV, eGFR and urine
ACR at the TEMPO 4:4 baseline were due to the treatment ef-
fect of tolvaptan during TEMPO 3:4. Controlling for these and
other covariates previously shown to predict the response to tol-
vaptan (urine ACR and serum copeptin) [10, 11] uncovered a
significant effect of early intervention on TKV (4.15%) com-
parable to the effect of tolvaptan at the end of TEMPO 3:4 after
discounting the acute antisecretory effect (5%), as discussed
above.
TEMPO 4:4 demonstrated that the eGFR benefit, achieved at
the end of TEMPO 3:4 in the early-treated subjects, was main-
tained for an additional 2 years in TEMPO 4:4. Moreover,
eGFR slopes of early-treated subjects during TEMPO 4:4 were
FIGURE 6: Change from baseline in TKV and eGFR by imaging classiﬁcation. (A) Percentage change in TKV from TEMPO 3:4 baseline to
Month 24 in TEMPO 4:4 for subjects in class 2A–B and 1B (left panel) and class 1C, D, E (right panel). (B) Change in eGFR from TEMPO 3:4
baseline to Month 24 in TEMPO 4:4 for subjects in class 2A–B and 1B (left panel) and class 1C, D, E (right panel). Open circles and triangles
represent off-treatment time points.
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comparable and statistically non-inferior to those of the
delayed-treated subjects. The more frequent estimation of GFR
by serum creatinine, more acute onset and offset of hemo-
dynamic effects, and lesser impact of covariates such as gender
make the GFR endpoint more compatible with the design of
this open-label extension trial. These results, therefore, support
a disease-modifying effect of tolvaptan in slowing ADPKD pro-
gression, that is, renal function decline.
While it might be tempting to conclude from the divergent
TKV and eGFR outcomes of TEMPO 4:4 that the effects of tol-
vaptan on TKV and eGFR are unrelated, it is clear from the re-
sults of the longest, ongoing longitudinal natural history study
in ADPKD, the Consortium for Radiologic Studies of Polycystic
Kidney Disease (CRISP), that changes in TKV and eGFR are
not concurrent and that the increase in TKV precedes and sig-
nificantly predicts the change in eGFR [20, 21]. Nevertheless,
TEMPO 3:4 and TEMPO 4:4 also suggest that tolvaptan may
have effects on eGFR that are independent of changes in TKV.
TEMPO 3:4 showed that tolvaptan has an acute effect on eGFR
(replicated in the delayed-treated subjects in TEMPO 4:4),
which is rapidly reversible when the drug is discontinued even if
this occurs years later [8]. On the other hand, after prolonged
treatment, the acute reduction in cyst volume thought to be due
to an antisecretory effect of tolvaptan appears to take months to
FIGURE 7: Change from baseline in TKV and eGFR by genotype. (A) Percentage change in TKV from TEMPO 3:4 baseline to Month 24 in
TEMPO 4:4 for subjects with PKD2 (left panel), PKD1 non-truncating (NT, middle panel) and PKD1 truncating (T, right panel) genotypes.
(B) Change in eGFR from TEMPO 3:4 baseline to Month 24 in TEMPO 4:4 for subjects PKD2 (left panel), PKD1 non-truncating (NT, middle
panel) and PKD1 truncating (T, right panel) genotypes. Open circles and triangles represent off-treatment time points.
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reverse once the drug is discontinued. This suggests a persistent,
structural and not just functional effect of tolvaptan on the se-
cretory epithelium. Therefore, we cannot exclude the possibility
that tolvaptan is renoprotective through a renal hemodynamic
effect [22] or potentially other mechanisms in addition to its
antisecretory and antiproliferative effects on cystic epithelium.
In previous post hoc analyses of TEMPO 3:4, we found that
the treatment effect of tolvaptan on TKV and eGFR was greater
and/or easier to demonstrate in the subjects with more severe or
more advanced disease. The post hoc analyses of TEMPO 4:4 in
the current study show that the subjects with image class 1C–E,
with truncating PKD1 mutations or with CKD 2–3 maintained
the treatment effect of tolvaptan not only on eGFR but also on
TKV for an additional 2 years in TEMPO 4:4. In smaller num-
bers of subjects with image classification 1A–B or with non-
truncating PKD1 or PKD2mutations, tolvaptan had no demon-
strable significant effect on TKV at the end of either TEMPO
3:4 or TEMPO 4:4. Interestingly, in CKD 1 subjects, tolvaptan
had a significant effect on TKV at the end of TEMPO 3:4 but it
was not maintained in TEMPO 4:4. This may be due to smaller
incremental effect of tolvaptan on TKV, relative to the initial
antisecretory effects during years 2 and 3 of TEMPO 3:4 in
CKD 1, compared with that seen in CKD 2 and 3 subjects. In
these subjects, TKV growth is faster and cyst expansion may be
more dependent on proliferation than secretion.
In general, the safety profile for tolvaptan in TEMPO 4:4 was
similar to that of the tolvaptan arm of TEMPO 3:4. Most ad-
verse events were related to the aquaretic effect of tolvaptan.
The incidence of hepatic events in the delayed-treated subjects
was similar to that observed in the tolvaptan-treated subjects
FIGURE 8: Change from baseline in TKV and eGFR by CKD stage. (A) Percent change in TKV from TEMPO 3:4 baseline to Month 24 in
TEMPO 4:4 for subjects in CKD 1 (left panel) and CKD 2/3 (right panel). (B) Change in eGFR from TEMPO 3:4 baseline to Month 24 in
TEMPO 4:4 for subjects in CKD 1 (left panel) and CKD 2/3 (right panel). Open circles and triangles represent off-treatment time points.
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in TEMPO 3:4. One subject in the delayed-treatment group
met the criterion for Hy’s Law and has been previously
reported [15].
Despite significant strengths, including the large number of
subjects treated with tolvaptan for at least 5 years and the com-
parison of early and delayed interventions, TEMPO 4:4 has sev-
eral obvious limitations, including a design that did not take
into account the changing treatment effect of tolvaptan over
time, the changing rate of TKV growth over time, loss of ran-
domization from TEMPO 3:4 due to unequal distribution of
dropouts and optional rollover to open-label extension with
highly variable intervals between the two studies.
In summary, TEMPO 4:4 did not demonstrate a sustained
expected beneficial difference in TKV achieved during TEMPO
3:4 (primary endpoint of the trial) and non-inferiority in the
slope of TKV growth during TEMPO 4:4 in early- compared
with delayed-treated subjects. On the other hand, the trial
showed a sustained beneficial effect on eGFR and non-
inferiority in the slopes of eGFR, supporting a disease-modify-
ing effect. While the TKV endpoint did not meet its prespecified
statistical threshold for proof of disease modification, this may
be accounted for by unforeseen limitations when the trial was
designed, including loss of randomization and baseline imbal-
ances ensuing TEMPO 3:4.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxfordjour
nals.org. The investigators in the TEMPO 4:4 trial are listed in
Supplementary Table S2.
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Hereditary polycystic kidney disease is characterized by
lymphopenia across all stages of kidney dysfunction:
an observational study
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ABSTRACT
Background: Polycystic kidney disease (PKD) is characterized
by urinary tract infections and extrarenal abnormalities such as
an increased risk of cancer. As mutations in polycystin-1 and -2
are associated with decreased proliferation of immortalized
lymphoblastoid cells in PKD, we investigated whether lympho-
penia could be an unrecognized trait of PKD.
Methods: We studied 700 kidney transplant recipients with
(n¼ 126) or without PKD at the time of kidney transplantation
between 1 January 2003 and 31 December 2014 at Ghent
University Hospital. We also studied 204 patients with chronic
kidney disease (CKD) with PKD and 204 matched CKD patients
without PKD across comparable CKD strata with assessment
between 1 January 1999 and 1 February 2016 at three renal out-
patient clinics. We compared lymphocyte counts with multiple
linear regression analysis to adjust for potential confounders. We
analysed ﬂow cytometric immunophenotyping data and other
haematological parameters.
Results: Lymphocyte counts were 264/mL [95% conﬁdence
interval (CI) 144–384] and 345/mL (95% CI 245–445) (both
P< 0.001) lower in the end-stage kidney disease (ESKD) and
CKD cohort, respectively, after adjustment for age, sex, ln(C-
reactive protein) and estimated glomerular ﬁltration rate (in the
CKD cohort only). In particular, CD8þ T and B lymphocytes
were signiﬁcantly lower in transplant recipients with versus
without PKD (P< 0.001 for both). Thrombocyte and monocyte
counts were lower in patients with versus without PKD in both
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